-+ 0.00%
-+ 0.00%
-+ 0.00%
AusperBio Reports Sustained Functional Cure up to 15 Months Off All HBV Treatment in Treatment-Naïve and NA-Treated Patients with Chronic Hepatitis B
Share
Listen to the news

Long-term follow-up supports AHB-137 as a potential finite-duration therapy; data featured in two late-breaking oral presentations at AASLD The Liver Meeting® 2026

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending